Blue Jet Healthcare Ltd
Incorporated in 1968, Blue Jet Healthcare (earlier called Jet Chemicals Pvt Ltd) is a pharmaceutical and healthcare ingredient & intermediate company and the first manufacturer of saccharin and its salts (artificial sweeteners) in India.[1]
- Market Cap ₹ 11,284 Cr.
- Current Price ₹ 596
- High / Low ₹ 768 / 325
- Stock P/E 48.0
- Book Value ₹ 78.4
- Dividend Yield 0.20 %
- ROCE 26.1 %
- ROE 19.4 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 23.6%
Cons
- Stock is trading at 7.60 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 538 | 499 | 683 | 721 | 712 | 1,030 | 947 | 886 | |
| 325 | 292 | 434 | 502 | 481 | 652 | 653 | 614 | |
| Operating Profit | 214 | 207 | 249 | 219 | 231 | 378 | 294 | 271 |
| OPM % | 40% | 41% | 36% | 30% | 32% | 37% | 31% | 31% |
| 6 | 9 | 19 | 24 | 18 | 46 | 69 | 76 | |
| Interest | 7 | 5 | 3 | 1 | 0 | 0 | 6 | 6 |
| Depreciation | 18 | 20 | 22 | 25 | 28 | 18 | 24 | 25 |
| Profit before tax | 194 | 190 | 243 | 217 | 220 | 406 | 333 | 316 |
| Tax % | 25% | 26% | 25% | 26% | 26% | 25% | 25% | |
| 145 | 142 | 182 | 160 | 164 | 305 | 248 | 235 | |
| EPS in Rs | 24,118.33 | 1,428.77 | 10.47 | 9.23 | 9.44 | 17.59 | 14.29 | 13.55 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 11% | 7% | 8% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 10% |
| TTM: | -28% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 11% |
| 3 Years: | 15% |
| TTM: | -34% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -23% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 24% |
| Last Year: | 19% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.60 | 10 | 35 | 35 | 35 | 35 | 35 |
| Reserves | 198 | 330 | 487 | 647 | 811 | 1,098 | 1,325 |
| 74 | 52 | 19 | 5 | 3 | 21 | 44 | |
| 92 | 142 | 173 | 176 | 211 | 263 | 238 | |
| Total Liabilities | 364 | 534 | 713 | 862 | 1,059 | 1,418 | 1,641 |
| 107 | 139 | 156 | 151 | 172 | 300 | 316 | |
| CWIP | 2 | 3 | 3 | 30 | 147 | 89 | 301 |
| Investments | 26 | 37 | 94 | 189 | 250 | 187 | 252 |
| 229 | 355 | 460 | 491 | 489 | 841 | 771 | |
| Total Assets | 364 | 534 | 713 | 862 | 1,059 | 1,418 | 1,641 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 122 | 137 | 146 | 142 | 241 | 46 | 334 | |
| -45 | -61 | -76 | -147 | -264 | -35 | -276 | |
| -72 | -21 | -56 | -4 | -2 | -19 | -31 | |
| Net Cash Flow | 5 | 55 | 14 | -10 | -24 | -8 | 28 |
| Free Cash Flow | 106 | 85 | 125 | 83 | 68 | -34 | 115 |
| CFO/OP | 80% | 66% | 70% | 92% | 109% | 36% | 151% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 80 | 105 | 121 | 121 | 91 | 124 | 131 |
| Inventory Days | 120 | 253 | 133 | 137 | 151 | 209 | 157 |
| Days Payable | 90 | 128 | 72 | 58 | 35 | 70 | 48 |
| Cash Conversion Cycle | 110 | 231 | 183 | 199 | 206 | 262 | 240 |
| Working Capital Days | 55 | 89 | 103 | 120 | 92 | 157 | 136 |
| ROCE % | 58% | 53% | 35% | 30% | 40% | 26% |
Insights
In beta| Mar 2018 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Revenue from Contrast Media Intermediates INR mn |
|
||||||
| Revenue from High Intensity Sweeteners INR mn |
|||||||
| Revenue from Pharma Intermediates & API INR mn |
|||||||
| Reaction Capacity KL |
|||||||
| Capacity Utilization % |
|||||||
| Commercialized Product Portfolio count |
|||||||
| Customer Count count |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Intimation of Newspaper Publication of information regarding 58th Annual General Meeting through VC/Other Audio Visual Means
-
Business Responsibility and Sustainability Reporting (BRSR)
- Blue Jet Healthcare filed its FY2025-26 Business Responsibility and Sustainability Report on August 18, 2026.
-
Notice Of The 58Th Annual General Meeting Of Blue Jet Healthcare Limited
- 58th AGM on Sept 21, 2026; ₹1.20 dividend, auditor and director reappointments proposed.
-
Reg. 34 (1) Annual Report.
- FY2025-26 annual report filed; 58th AGM scheduled for September 21, 2026 via VC/OAVM.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Intimation of Newspaper Publication regarding 58th Annual General Meeting through Video Conferencing/Other Audio Visual Means to be held on 21st September, 2026.
Annual reports
Concalls
-
Aug 2026Transcript PPT REC
-
May 2026Transcript PPT REC
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Jul 2025Transcript PPT REC
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Oct 2024TranscriptAI SummaryPPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT
Product Portfolio
A) Contrast Media Intermediates (67.7% of FY24 revenue)[1]
Contrast media are chemical agents that enhance imaging clarity for diagnostic purposes, making tissues more visible under X-rays, CT scans, MRIs, and ultrasounds. The company supplies critical starting and advanced intermediates to the world's top contrast media manufacturers.